Mechanism-based Suppression of Cancer by Targeting DNA-Replicating Enzymes


Cite item

Full Text

Abstract

The human genetic structure undergoes continuous wear and tear process due to the mere presence of extrinsic as well as intrinsic factors. In normal physiological cells, DNA damage initiates various checkpoints that may activate the repair system or induce apoptosis that helps maintain cellular integrity. While in cancerous cells, due to alterations in signaling pathways and defective checkpoints, there exists a marked deviation of error-free DNA repairing/synthesis. Currently, cancer therapy targeting the DNA damage response shows significant therapeutic potential by tailoring the therapy from non-specific to tumor-specific activity. Recently, numerous drugs that target the DNA replicating enzymes have been approved or some are under clinical trial. Drugs like PARP and PARG inhibitors showed sweeping effects against cancer cells. This review highlights the mechanistic study of different drug categories that target DNA replication and thus depicts the futuristic approach of targeted therapy.

About the authors

Preeti Arya

, Guru Gobind Singh College of Pharmacy

Email: info@benthamscience.net

Hitesh Malhotra

, Guru Gobind Singh College of Pharmacy

Email: info@benthamscience.net

Benu Chaudhary

, Guru Gobind Singh College of Pharmacy

Email: info@benthamscience.net

Amrit Sarwara

, Guru Gobind Singh College of Pharmacy

Email: info@benthamscience.net

Rajat Goyal

MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University)

Email: info@benthamscience.net

Chunpeng Wan

Jiangxi Key Laboratory for Postharvest Technology and Nondestructive Testing of Fruits & Vegetables, College of Agronomy, Jiangxi Agricultural University

Author for correspondence.
Email: info@benthamscience.net

Dinesh Mishra

, Indore Institute of Pharmacy,

Email: info@benthamscience.net

Rupesh Gautam

Indore Institute of Pharmacy, Indore Institute of Pharmacy

Author for correspondence.
Email: info@benthamscience.net

References

  1. Hanahan, D.; Weinberg, RA Hallmarks of cancer: The next generation. Cell., 2011, 144(5), 646-674.
  2. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.K.; Hampton, G.M.; Wahl, G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell, 2002, 9(5), 1031-1044. doi: 10.1016/S1097-2765(02)00520-8 PMID: 12049739
  3. Tubbs, A.; Nussenzweig, A. Endogenous DNA damage as a source of genomic instability in cancer. Cell, 2017, 168(4), 644-656. doi: 10.1016/j.cell.2017.01.002 PMID: 28187286
  4. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140(6), 883-899. doi: 10.1016/j.cell.2010.01.025 PMID: 20303878
  5. Mateo, J.; Lord, C.J.; Serra, V.; Tutt, A.; Balmaña, J.; Castroviejo-Bermejo, M.; Cruz, C.; Oaknin, A.; Kaye, S.B.; de Bono, J.S. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol., 2019, 30(9), 1437-1447. doi: 10.1093/annonc/mdz192 PMID: 31218365
  6. Jeggo, P.A.; Pearl, L.H.; Carr, A.M. DNA repair, genome stability and cancer: A historical perspective. Nat. Rev. Cancer, 2016, 16(1), 35-42. doi: 10.1038/nrc.2015.4 PMID: 26667849
  7. Chatterjee, N.; Walker, G.C. Mechanisms of DNA damage, repair, and mutagenesis. Environ. Mol. Mutagen., 2017, 58(5), 235-263. doi: 10.1002/em.22087 PMID: 28485537
  8. Langelier, M.F.; Riccio, A.A.; Pascal, J.M. PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res., 2014, 42(12), 7762-7775. doi: 10.1093/nar/gku474 PMID: 24928857
  9. Eustermann, S.; Wu, W.F.; Langelier, M.F.; Yang, J.C.; Easton, L.E.; Riccio, A.A.; Pascal, J.M.; Neuhaus, D. Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1. Mol. Cell, 2015, 60(5), 742-754. doi: 10.1016/j.molcel.2015.10.032 PMID: 26626479
  10. Langelier, M.F.; Planck, J.L.; Roy, S.; Pascal, J.M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science, 2012, 336(6082), 728-732. doi: 10.1126/science.1216338 PMID: 22582261
  11. Bétermier, M.; Bertrand, P.; Lopez, B.S. Is non-homologous end-joining really an inherently error-prone process? PLoS Genet., 2014, 10(1), e1004086. doi: 10.1371/journal.pgen.1004086 PMID: 24453986
  12. Jiang, X.; Li, X.; Li, W.; Bai, H.; Zhang, Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J. Cell. Mol. Med., 2019, 23(4), 2303-2313. doi: 10.1111/jcmm.14133 PMID: 30672100
  13. Champoux, J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem., 2001, 70(1), 369-413. doi: 10.1146/annurev.biochem.70.1.369 PMID: 11395412
  14. Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol., 2002, 3(6), 430-440. doi: 10.1038/nrm831 PMID: 12042765
  15. Corbett, K.D.; Berger, J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 2004, 33(1), 95-118. doi: 10.1146/annurev.biophys.33.110502.140357 PMID: 15139806
  16. Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer, 2009, 9(5), 327-337. doi: 10.1038/nrc2608 PMID: 19377505
  17. Vos, S.M.; Tretter, E.M.; Schmidt, B.H.; Berger, J.M. All tangled up: How cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol., 2011, 12(12), 827-841. doi: 10.1038/nrm3228 PMID: 22108601
  18. Chen, S.H.; Chan, N.L.; Hsieh, T. New mechanistic and functional insights into DNA topoisomerases. Annu. Rev. Biochem., 2013, 82(1), 139-170. doi: 10.1146/annurev-biochem-061809-100002 PMID: 23495937
  19. Pommier, Y.; Sun, Y.; Huang, S.N.; Nitiss, J.L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol., 2016, 17(11), 703-721. doi: 10.1038/nrm.2016.111 PMID: 27649880
  20. Krishnakumar, R.; Kraus, W.L. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol. Cell, 2010, 39(1), 8-24. doi: 10.1016/j.molcel.2010.06.017 PMID: 20603072
  21. Hu, Y.; Petit, S.A.; Ficarro, S.B.; Toomire, K.J.; Xie, A.; Lim, E.; Cao, S.A.; Park, E.; Eck, M.J.; Scully, R.; Brown, M.; Marto, J.A.; Livingston, D.M. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov., 2014, 4(12), 1430-1447. doi: 10.1158/2159-8290.CD-13-0891 PMID: 25252691
  22. Zhao, W.; Hu, H.; Mo, Q.; Guan, Y.; Li, Y.; Du, Y.; Li, L. Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells. Int. J. Clin. Exp. Pathol., 2019, 12(10), 3915-3920. PMID: 31933782
  23. Hanzlikova, H.; Gittens, W.; Krejcikova, K.; Zeng, Z.; Caldecott, K.W. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res., 2017, 45(5), 2546-2557. PMID: 27965414
  24. Gogola, E.; Duarte, A.A.; de Ruiter, J.R.; Wiegant, W.W.; Schmid, J.A.; de Bruijn, R.; James, D.I.; Guerrero, L.S.; Vis, D.J.; Annunziato, S.; van den Broek, B.; Barazas, M.; Kersbergen, A.; van de Ven, M.; Tarsounas, M.; Ogilvie, D.J.; van Vugt, M.; Wessels, L.F.A.; Bartkova, J.; Gromova, I.; Andújar-Sánchez, M.; Bartek, J.; Lopes, M.; van Attikum, H.; Borst, P.; Jonkers, J.; Rottenberg, S. Selective loss of PARG restores PARylation and counteracts parp inhibitor-mediated synthetic lethality. Cancer Cell, 2018, 33(6), 1078-1093. doi: 10.1016/j.ccell.2018.05.008 PMID: 29894693
  25. Heeke, A.L.; Pishvaian, M.J.; Lynce, F.; Xiu, J.; Brody, J.R.; Chen, W.J.; Baker, T.M.; Marshall, J.L.; Isaacs, C. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis. Oncol., 2018, 2018(2), 1-13. doi: 10.1200/PO.17.00286 PMID: 30234181
  26. Wang, D.; Li, C.; Zhang, Y.; Wang, M.; Jiang, N.; Xiang, L.; Li, T.; Roberts, T.M.; Zhao, J.J.; Cheng, H.; Liu, P. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol. Oncol., 2016, 142(3), 548-556. doi: 10.1016/j.ygyno.2016.07.092 PMID: 27426307
  27. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.M.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134. doi: 10.1056/NEJMoa0900212 PMID: 19553641
  28. Coleman, R.L.; Fleming, G.F.; Brady, M.F.; Swisher, E.M.; Steffensen, K.D.; Friedlander, M.; Okamoto, A.; Moore, K.N.; Efrat Ben-Baruch, N.; Werner, T.L.; Cloven, N.G.; Oaknin, A.; DiSilvestro, P.A.; Morgan, M.A.; Nam, J.H.; Leath, C.A., III; Nicum, S.; Hagemann, A.R.; Littell, R.D.; Cella, D.; Baron-Hay, S.; Garcia-Donas, J.; Mizuno, M.; Bell-McGuinn, K.; Sullivan, D.M.; Bach, B.A.; Bhattacharya, S.; Ratajczak, C.K.; Ansell, P.J.; Dinh, M.H.; Aghajanian, C.; Bookman, M.A. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2403-2415. doi: 10.1056/NEJMoa1909707 PMID: 31562800
  29. Tuli, R.; Shiao, S.L.; Nissen, N.; Tighiouart, M.; Kim, S.; Osipov, A.; Bryant, M.; Ristow, L.; Placencio-Hickok, V.; Hoffman, D.; Rokhsar, S.; Scher, K.; Klempner, S.J.; Noe, P.; Davis, M.J.; Wachsman, A.; Lo, S.; Jamil, L.; Sandler, H.; Piantadosi, S.; Hendifar, A. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine, 2019, 40, 375-381. doi: 10.1016/j.ebiom.2018.12.060 PMID: 30635165
  30. Dockery, L.E.; Tew, W.P.; Ding, K.; Moore, K.N. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol. Oncol., 2017, 147(3), 509-513. doi: 10.1016/j.ygyno.2017.10.007 PMID: 29037805
  31. Okayama, H.; Edson, C.M.; Fukushima, M.; Ueda, K.; Hayaishi, O. Purification and properties of poly(adenosine diphosphate ribose) synthetase. J. Biol. Chem., 1977, 252(20), 7000-7005. doi: 10.1016/S0021-9258(19)66926-7 PMID: 198398
  32. Benjamin, R.C.; Gill, D.M. Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J. Biol. Chem., 1980, 255(21), 10502-10508. doi: 10.1016/S0021-9258(19)70491-8 PMID: 6253477
  33. Ray, C.A.; Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol., 2017, 18(10), 610-621. doi: 10.1038/nrm.2017.53 PMID: 28676700
  34. Nitiss, J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta Gene Struct. Expr., 1998, 1400(1-3), 63-81. doi: 10.1016/S0167-4781(98)00128-6 PMID: 9748506
  35. Pandey, A.; Makhija, P.; Prakash, G.C.; Anil, B.G. PARG inhibitors’ success: A long way to go! Curr. Enzym. Inhib., 2014, 10(2), 81-93. doi: 10.2174/1573408010666141126220225
  36. Stewart, L.; Redinbo, M.R.; Qiu, X.; Hol, W.G.J.; Champoux, J.J. A model for the mechanism of human topoisomerase. iScience, 1998, 279(5356), 1534-1541. doi: 10.1126/science.279.5356.1534 PMID: 9488652
  37. Berger, J.M.; Gamblin, S.J.; Harrison, S.C.; Wang, J.C. Structure and mechanism of DNA topoisomerase II. Nature, 1996, 379(6562), 225-232. doi: 10.1038/379225a0 PMID: 8538787
  38. Bates, A.D.; Maxwell, A. DNA supercoiling. In: DNA Topology; Rickwood, D., Ed.; IRL-Press Inc.: New York, 1993; pp. 17-45.
  39. Okoro, C.O.; Fatoki, T.H. Fatoki TH. A mini review of novel topoisomerase ii inhibitors as future anticancer agents. Int. J. Mol. Sci., 2023, 24(3), 2532. doi: 10.3390/ijms24032532 PMID: 36768852
  40. Hsiang, Y.H.; Liu, L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 1988, 48(7), 1722-1726. PMID: 2832051
  41. Muggia, F.M.; Creaven, P.J.; Hansen, H.H.; Cohen, M.H.; Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother. Rep., 1972, 56(4), 515-521. PMID: 5081595
  42. Masuda, N.; Fukuoka, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Negoro, S.; Nishioka, M.; Nakagawa, K.; Takada, M. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 1992, 10(8), 1225-1229. doi: 10.1200/JCO.1992.10.8.1225 PMID: 1321891
  43. Hertzberg, R.P.; Caranfa, M.J.; Holden, K.G.; Jakas, D.R.; Gallagher, G.; Mattern, M.R.; Mong, S.M.; Bartus, J.O.L.; Johnson, R.K.; Kingsbury, W.D. Modification of the hydroxylactone ring of camptothecin: Inibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 1989, 32(3), 715-720. doi: 10.1021/jm00123a038 PMID: 2537428
  44. Rivory, L.P.; Riou, J.F.; Haaz, M.C.; Sable, S.; Vuilhorgne, M.; Commerçon, A.; Pond, S.M.; Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 1996, 56(16), 3689-3694. PMID: 8706009
  45. Fukuoka, M.; Niitani, H.; Suzuki, A.; Motomiya, M.; Hasegawa, K.; Nishiwaki, Y.; Kuriyama, T.; Ariyoshi, Y.; Negoro, S.; Masuda, N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 1992, 10(1), 16-20. doi: 10.1200/JCO.1992.10.1.16 PMID: 1309380
  46. Ottaviani, A.; Welsch, J.; Agama, K.; Pommier, Y.; Desideri, A.; Baker, B.J.; Fiorani, P. From Antarctica to cancer research: A novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica. J. Enzyme Inhib. Med. Chem., 2022, 37(1), 1404-1410. doi: 10.1080/14756366.2022.2078320 PMID: 35603503
  47. Tsunoda, T.; Tanimura, H.; Hotta, T.; Tani, M.; Iwahashi, M.; Tanaka, H.; Matsuda, K.; Yamaue, H. In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer. Anticancer Res., 1999, 19(6B), 5451-5455. PMID: 10697576
  48. Frangoul, H.; Ames, M.M.; Mosher, R.B.; Reid, J.M.; Krailo, M.D.; Seibel, N.L.; Shaw, D.W.; Steinherz, P.G.; Whitlock, J.A.; Holcenberg, J.S. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: A report from the Children’s Cancer Group. Clin. Cancer Res., 1999, 5(12), 3956-3962. PMID: 10632325
  49. Bailly, C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem., 2000, 7(1), 39-58. doi: 10.2174/0929867003375489 PMID: 10637356
  50. Dahut, W.; Harold, N.; Takimoto, C.; Allegra, C.; Chen, A.; Hamilton, J.M.; Arbuck, S.; Sorensen, M.; Grollman, F.; Nakashima, H.; Lieberman, R.; Liang, M.; Corse, W.; Grem, J. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J. Clin. Oncol., 1996, 14(4), 1236-1244. doi: 10.1200/JCO.1996.14.4.1236 PMID: 8648379
  51. Zhou, B.N.; Johnson, R.K.; Mattern, M.R.; Wang, X.; Hecht, S.M.; Beck, H.T.; Ortiz, A.; Kingston, D.G.I. Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon. J. Nat. Prod., 2000, 63(2), 217-221. doi: 10.1021/np990442s PMID: 10691712
  52. Fleury, F.; Sukhanova, A.; Ianoul, A.; Devy, J.; Kudelina, I.; Duval, O.; Alix, A.J.P.; Jardillier, J.C.; Nabiev, I. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding. J. Biol. Chem., 2000, 275(5), 3501-3509. doi: 10.1074/jbc.275.5.3501 PMID: 10652345
  53. Mortensen, U.H.; Stevnsner, T.; Krogh, S.; Olesen, K.; Westergaard, O.; Bonven, B.J. Distamycin inhibition of topoisomerase I-DNA interaction: A mechanistic analysis. Nucleic Acids Res., 1990, 18(8), 1983-1989. doi: 10.1093/nar/18.8.1983 PMID: 2159632
  54. Wall, M.E.; Wani, M.C. Camptothecin and taxol: Discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res., 1995, 55(4), 753-760. PMID: 7850785
  55. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 1985, 260(27), 14873-14878. doi: 10.1016/S0021-9258(17)38654-4 PMID: 2997227
  56. Eng, W.K.; Faucette, L.; Johnson, R.K.; Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 1988, 34(6), 755-760. PMID: 2849043
  57. Ayusawa, D.; Arai, H.; Wataya, Y.; Seno, T. A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutat. Res., 1988, 200(1-2), 221-230. doi: 10.1016/0027-5107(88)90086-3 PMID: 2839770
  58. Nassan, M.A.; Aldhahrani, A.; Amer, H.H.; Elhenawy, A.; Swelum, A.A.; Ali, O.M.; Zaki, Y.H. Investigation of the anticancer effect of α-aminophosphonates and arylidine derivatives of 3-Acetyl-1-aminoquinolin-2(1H)-one on the DMBA model of breast cancer in albino rats with in silico prediction of their thymidylate synthase inhibitory effect. Molecules, 2022, 27(3), 756. doi: 10.3390/molecules27030756 PMID: 35164019
  59. Grem, J.L. Fluorinated pyrimidines. In: Cancer Chemotherapy: Principles and Practice; Chabner, B.A.; Collins, J.M., Eds.; J. B. Lippincott Company: Philadelphia, 1990, pp. 180-224.
  60. Shafer, C.M.; Lindvall, M.; Bellamacina, C.; Gesner, T.G.; Yabannavar, A.; Jia, W.; Lin, S.; Walter, A. 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(16), 4482-4485. doi: 10.1016/j.bmcl.2008.07.061 PMID: 18672368
  61. Salerno, D.; Hasham, M.G.; Marshall, R.; Garriga, J.; Tsygankov, A.Y.; Graña, X. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene, 2007, 405(1-2), 65-78. doi: 10.1016/j.gene.2007.09.010 PMID: 17949927
  62. Swords, R.; Mahalingam, D.; O’Dwyer, M.; Santocanale, C.; Kelly, K.; Carew, J.; Giles, F. Cdc7 kinase – A new target for drug development. Eur. J. Cancer, 2010, 46(1), 33-40. doi: 10.1016/j.ejca.2009.09.020 PMID: 19815406
  63. Montagnoli, A.; Bosotti, R.; Villa, F.; Rialland, M.; Brotherton, D.; Mercurio, C.; Berthelsen, J.; Santocanale, C. Drf1, a novel regulatory subunit for human Cdc7 kinase. EMBO J., 2002, 21(12), 3171-3181. doi: 10.1093/emboj/cdf290 PMID: 12065429
  64. Manohar, S.M.; Joshi, K.S. Promising anticancer activity of multitarget cyclin dependent kinase inhibitors against human colorectal carcinoma cells. Curr. Mol. Pharmacol., 2022, 15(7), 1024-1033. doi: 10.2174/1874467215666220124125809 PMID: 35068399

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers